We had hypothesized that IL-1β would contribute to the progression of CKD in T2DM and used a novel IL-1β-specific antibody that can neutralize its biological effects in a validated mouse model of CKD in T2DM. The gene discussed is IL1B; the disease is chronic kidney disease.